Literature DB >> 3894525

Spreading and enhanced motility of human keratinocytes on fibronectin.

E J O'Keefe, R E Payne, N Russell, D T Woodley.   

Abstract

Soluble human plasma fibronectin or collagen types I or IV, when preincubated with tissue culture plastic dishes, were effective spreading agents for cultured human keratinocytes and increased spreading in a time-and concentration-dependent manner. Spreading on fibronectin, but not on type IV collagen, was inhibited by antifibronectin; therefore, the contribution of fibronectin to the spreading activity of the natural matrix produced by keratinocytes could not be determined using antifibronectin. Fibronectin mediated spreading at both high (1.1 mM) and low (0.1 mM) Ca++ concentrations, and spreading was not altered by cycloheximide. Insoluble fibronectin deposited by keratinocytes correlated with phagokinetic tracks on particulate gold salts, and added fibronectin, as well as type I collagen and type IV collagen, enhanced motility of keratinocytes. These studies show that production of fibronectin and responsiveness to it are similar in fibroblasts and keratinocytes and demonstrate that fibronectin can act as a matrix factor for keratinocytes.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3894525     DOI: 10.1111/1523-1747.ep12276531

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  19 in total

1.  Increased levels of plasma vitronectin in severe psoriatic patients.

Authors:  T Nogita; M Kawashima
Journal:  Arch Dermatol Res       Date:  1992       Impact factor: 3.017

2.  Regulation of extracellular matrix proteins and integrin cell substratum adhesion receptors on epithelium during cutaneous human wound healing in vivo.

Authors:  I Juhasz; G F Murphy; H C Yan; M Herlyn; S M Albelda
Journal:  Am J Pathol       Date:  1993-11       Impact factor: 4.307

3.  The time-dependent expression of keratins 5 and 13 during the reepithelialization of human skin wounds.

Authors:  P Betz; A Nerlich; J Tübel; R Penning; W Eisenmenger
Journal:  Int J Legal Med       Date:  1993       Impact factor: 2.686

4.  Specific affinity between fibronectin and the epidermolysis bullosa acquisita antigen.

Authors:  D T Woodley; E J O'Keefe; J A McDonald; M J Reese; R A Briggaman; W R Gammon
Journal:  J Clin Invest       Date:  1987-06       Impact factor: 14.808

5.  Expression of integrins and basement membrane components by wound keratinocytes.

Authors:  H Larjava; T Salo; K Haapasalmi; R H Kramer; J Heino
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

6.  Cdc42 and p190RhoGAP activation by CCN2 regulates cell spreading and polarity and induces actin disassembly in migrating keratinocytes.

Authors:  Elizabeth Kiwanuka; Cameron Cy Lee; Florian Hackl; Edward J Caterson; Johan Pe Junker; Bengt Gerdin; Elof Eriksson
Journal:  Int Wound J       Date:  2014-09-03       Impact factor: 3.315

7.  Hypoxia increases human keratinocyte motility on connective tissue.

Authors:  E A O'Toole; M P Marinkovich; C L Peavey; M R Amieva; H Furthmayr; T A Mustoe; D T Woodley
Journal:  J Clin Invest       Date:  1997-12-01       Impact factor: 14.808

8.  Localization of integrin receptors for fibronectin, collagen, and laminin in human skin. Variable expression in basal and squamous cell carcinomas.

Authors:  J Peltonen; H Larjava; S Jaakkola; H Gralnick; S K Akiyama; S S Yamada; K M Yamada; J Uitto
Journal:  J Clin Invest       Date:  1989-12       Impact factor: 14.808

9.  Upregulation of chemokine (C-C motif) ligand 20 in adult epidermal keratinocytes in direct current electric fields.

Authors:  Jessica Amber Jennings; Dongquan Chen; Dale S Feldman
Journal:  Arch Dermatol Res       Date:  2009-09-26       Impact factor: 3.017

10.  Fibronectin mediates adherence of rat alveolar type II epithelial cells via the fibroblastic cell-attachment domain.

Authors:  R A Clark; R J Mason; J M Folkvord; J A McDonald
Journal:  J Clin Invest       Date:  1986-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.